Molecular chaperones and co-chaperones in Parkinson disease - Test2 - elhamkhani - TriplyDB

Molecular chaperones and co-chaperones in Parkinson disease

Molecular chaperones and co-chaperones in Parkinson disease

http://www.wikidata.org/entity/Q26828834

about

Emerging novel concept of chaperone therapies for protein misfolding diseases Protein degradation pathways in Parkinson's disease: curse or blessing Chronic treatment with novel small molecule Hsp90 inhibitors rescues striatal dopamine levels but not α-synuclein-induced neuronal cell loss Molecular chaperones and protein folding as therapeutic targets in Parkinson's disease and other synucleinopathies Late-onset dementia: a mosaic of prototypical pathologies modifiable by diet and lifestyle.Alpha-synuclein levels in blood plasma decline with healthy aging.Ovarian steroids regulate gene expression related to DNA repair and neurodegenerative diseases in serotonin neurons of macaques.A Novel Hsp90 Inhibitor Activates Compensatory Heat Shock Protein Responses and Autophagy and Alleviates Mutant A53T α-Synuclein Toxicity.Identification of chaperones in a MPP+-induced and ATRA/TPA-differentiated SH-SY5Y cell PD model.Mechanisms underlying synaptic vulnerability and degeneration in neurodegenerative disease.Insights on the interaction of alpha-synuclein and metals in the pathophysiology of Parkinson's disease.Lamotrigine Attenuates Proteasome Inhibition-Induced Apoptosis by Suppressing the Activation of the Mitochondrial Pathway and the Caspase-8- and Bid-Dependent Pathways.How Studies of the Serotonin System in Macaque Models of Menopause Relate to Alzheimer's Disease1.Discovery of the neuroprotective effects of alvespimycin by computational prioritization of potential anti-Parkinson agents.Heat shock protein 90 is a potential therapeutic target for ameliorating skeletal muscle abnormalities in Parkinson's disease Inside-out: extracellular roles for heat shock proteins.Flavanonol taxifolin attenuates proteasome inhibition-induced apoptosis in differentiated PC12 cells by suppressing cell death process.3,4,5-tricaffeoylquinic acid attenuates proteasome inhibition-mediated programmed cell death in differentiated PC12 cells.Alpha-synuclein, proteotoxicity and Parkinson's disease: Search for neuroprotective therapy.Factor inhibiting HIF1-A novel target of SUMOylation in the human placenta.Exosomal secretion of α-synuclein as protective mechanism after upstream blockage of macroautophagy.

P2860

Q27002907-516FEEB4-91AD-4B52-95DD-8F1FFB8CCE52 Q27026029-4E400347-5D6C-4571-B2A7-67CDA611A712 Q28538890-C5146859-4F9A-4949-805A-56DB80BC68E7 Q33715640-14D17C01-296F-47F3-B25D-C21D18168BDF Q33817811-F82F737E-E76F-4F4B-86D9-0ECF355C6ACD Q35284843-FCBAF2FB-D744-4B3B-AC16-E941E7E4D1ED Q35544686-DC3B90D6-14F2-4204-B0C6-1CA5329B76A1 Q36316808-AEB7EA55-1365-4CC8-ABC4-155FF2C2F43C Q37553863-9EDCFBC8-9D74-4145-9574-94FEAEAC91DA Q38071648-9A73597F-C3D3-4E9E-BCAC-E87865FC2D6A Q38343049-765D7582-A96C-4C22-91A5-6F5DCF611D27 Q38768222-253314E5-9600-41B2-87EC-D7BEBB7F143E Q38962789-FC83301E-D1E6-446C-856B-02B7679A638E Q39048969-84CCD014-21E1-4A44-A481-AEDFFFC99336 Q42845134-4CA23F2C-6671-4A86-92E5-A56AE783B697 Q46181154-CF064934-571E-4179-885A-19CC68D29E73 Q46802646-75DA1E93-D3D0-4F85-8BD0-F99F2C38382A Q46894541-DCE47D70-4432-4D38-BD5B-D1C9CA469F1D Q47348189-2235037F-9A03-410C-86A8-8466AF4E5A93 Q49211105-9ED0620C-D03C-4B22-BAE5-5884D021FBFF Q55617564-DCD44CC9-5C3E-4690-9925-A3C58191E2E7

P2860

Molecular chaperones and co-chaperones in Parkinson disease

http://www.wikidata.org/entity/Q26828834

description

2012 nî lūn-bûn

@nan

2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Molecular chaperones and co-chaperones in Parkinson disease

@ast

Molecular chaperones and co-chaperones in Parkinson disease

@en

Molecular chaperones and co-chaperones in Parkinson disease

@nl

type

label

Molecular chaperones and co-chaperones in Parkinson disease

@ast

Molecular chaperones and co-chaperones in Parkinson disease

@en

Molecular chaperones and co-chaperones in Parkinson disease

@nl

prefLabel

Molecular chaperones and co-chaperones in Parkinson disease

@ast

Molecular chaperones and co-chaperones in Parkinson disease

@en

Molecular chaperones and co-chaperones in Parkinson disease

@nl

P1433

Q26828834-35BD6FCD-9B24-467F-B25E-D553B7A386A9

P1476

Q26828834-BE8723CF-DE43-4904-A46E-A58480EC5909

P2093

Q26828834-652EEB86-DCCC-4D37-BE59-DF24CB8589B7

Q26828834-6633D2C5-0F89-4B84-BC48-948C838E77EC

P2860

Q26828834-06DB4D0D-3859-4A46-B26F-15524ABB1F95

Q26828834-07E547DE-68C3-4143-835B-4A08B4BAECD8

Q26828834-098192BC-0A38-497C-AC80-1C157106CCA4

Q26828834-09ADA374-5021-497C-BAF2-C0CF5CB5043E

Q26828834-09B556D1-DBEE-4CF7-A4AE-4BBFD6C4EEE5

Q26828834-0CF744E2-E113-4767-A0B8-86EB246561BD

Q26828834-11C3778C-0C79-4235-A94A-A2FC5C1A4806

Q26828834-1845A3D4-6FAE-4577-9568-B847D7B1F291

Q26828834-203490F2-982F-43B3-88DA-61BB073F069A

Q26828834-231391DF-6EA9-4D64-BADE-A2309F4C3F79

P304

Q26828834-51375696-5377-4BB2-B297-17BD5341ACB9

P31

Q26828834-D7B00E9C-8A89-433F-AF74-364B9EB9A2A8

P356

Q26828834-8685BEC5-37B6-4CCA-A0E2-871E85A8A78B

P407

Q26828834-4B5267E8-0880-443D-8196-7583FF17D799

P433

Q26828834-AA9FB747-B6FC-4C3D-B8B9-7965716FACC5

P478

Q26828834-DF17ED3D-A62C-4542-B6B3-A6D661E5E398

P50

Q26828834-E74ADD85-8BA6-42AE-A124-5E9FD1858525

P577

Q26828834-8320D3E6-AF71-4106-8041-4B1E1643A193

P5875

Q26828834-9107328D-243C-4974-96BE-74E5B2E1036F

P698

Q26828834-265C4C0B-0E26-45F0-B1F2-F896E9E05C35

P921

Q26828834-509889B3-32B1-4538-B8EC-1416A33A4992

Q26828834-81E9E85D-C673-4BF5-A784-04A5B5D4ED14

P932

Q26828834-0EF7DA65-24DD-4894-BCC0-1C06599E72FD

P356

1073858412441372

P1433

The Neuroscientist

P1476

Molecular chaperones and co-chaperones in Parkinson disease

@en

P2093

Hemi Dimant

http://www.w3.org/2001/XMLSchema#string

Pamela J McLean

http://www.w3.org/2001/XMLSchema#string

P2860

The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins

Molecular markers of early Parkinson's disease based on gene expression in blood

Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism

Chaperone proteostasis in Parkinson's disease: stabilization of the Hsp70/alpha-synuclein complex by Hip

Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models

BAG5 inhibits parkin and enhances dopaminergic neuron degeneration

Activation of chaperone-mediated autophagy during oxidative stress

Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation.

Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease

alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies

P304

589-601

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1073858412441372

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P50

Darius Ebrahimi-Fakhari

P577

2012-07-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230565660

http://www.w3.org/2001/XMLSchema#string

P698

22829394

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

molecular chaperones

P932

3904222

http://www.w3.org/2001/XMLSchema#string